Repligen Corporation (NASDAQ:RGEN) Given Average Rating of “Moderate Buy” by Analysts

Repligen Corporation (NASDAQ:RGEN) has received an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $177.9167.

RGEN has been the subject of a number of research reports. Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. Jefferies Financial Group set a $160.00 price target on shares of Repligen and gave the company a “hold” rating in a research report on Tuesday, October 28th. Wells Fargo & Company boosted their price target on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. UBS Group upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Finally, Canaccord Genuity Group lifted their price objective on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a report on Wednesday, October 29th.

Repligen Price Performance

RGEN stock opened at $136.44 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14. The company’s 50-day moving average is $159.23 and its 200-day moving average is $145.84. The stock has a market capitalization of $7.68 billion, a PE ratio of 6,825.41, a price-to-earnings-growth ratio of 2.49 and a beta of 1.13. Repligen has a 1 year low of $102.96 and a 1 year high of $175.77.

Insider Transactions at Repligen

In related news, COO James Bylund sold 2,191 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares in the company, valued at approximately $3,254,039.20. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Karen A. Dawes sold 275 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director directly owned 91,821 shares of the company’s stock, valued at $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 4,657 shares of company stock valued at $706,877 in the last quarter. Company insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently made changes to their positions in RGEN. Measured Wealth Private Client Group LLC bought a new stake in Repligen in the 3rd quarter worth about $29,000. Bayforest Capital Ltd bought a new position in shares of Repligen in the fourth quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC purchased a new stake in shares of Repligen during the fourth quarter valued at approximately $33,000. Los Angeles Capital Management LLC purchased a new stake in shares of Repligen during the fourth quarter valued at approximately $36,000. Finally, Hantz Financial Services Inc. lifted its holdings in Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 293 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.